These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30361380)

  • 1. Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.
    De Rose F; Braeuer M; Braesch-Andersen S; Otto AM; Steiger K; Reder S; Mall S; Nekolla S; Schwaiger M; Weber WA; Bartolazzi A; D'Alessandria C
    J Nucl Med; 2019 Jun; 60(6):770-776. PubMed ID: 30361380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive
    Peplau E; De Rose F; Reder S; Mittelhäuser M; Scafetta G; Schwaiger M; Weber WA; Bartolazzi A; Skerra A; D'Alessandria C
    Thyroid; 2020 Sep; 30(9):1314-1326. PubMed ID: 32200708
    [No Abstract]   [Full Text] [Related]  

  • 3. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.
    Parent EE; Gleba JJ; Knight JA; Kenderian SJ; Copland JA; Cai H
    Mol Imaging Biol; 2024 Oct; 26(5):847-857. PubMed ID: 39174789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (
    Varasteh Z; De Rose F; Mohanta S; Li Y; Zhang X; Miritsch B; Scafetta G; Yin C; Sager HB; Glasl S; Gorpas D; Habenicht AJR; Ntziachristos V; Weber WA; Bartolazzi A; Schwaiger M; D'Alessandria C
    Theranostics; 2021; 11(4):1864-1876. PubMed ID: 33408786
    [No Abstract]   [Full Text] [Related]  

  • 5. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3.
    D'Alessandria C; Braesch-Andersen S; Bejo K; Reder S; Blechert B; Schwaiger M; Bartolazzi A
    Cancer Res; 2016 Jun; 76(12):3583-92. PubMed ID: 27216181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
    Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
    Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
    Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
    J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
    Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
    Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
    Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
    Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
    Wächter S; Wunderlich A; Greene BH; Roth S; Elxnat M; Fellinger SA; Verburg FA; Luster M; Bartsch DK; Di Fazio P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [
    Gimblet GR; Houson HA; Whitt J; Reddy P; Copland JA; Kenderian SS; Szkudlinski MW; Jaskula-Sztul R; Lapi SE
    Mol Pharm; 2024 Aug; 21(8):3889-3896. PubMed ID: 38976794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of microRNA-875-5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium-iodide symporter.
    Tang Y; Meng X; Yu X; Shang H; Chen S; Liao L; Dong J
    J Endocrinol Invest; 2020 Apr; 43(4):439-450. PubMed ID: 31612419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
    Chai W; Ye F; Zeng L; Li Y; Yang L
    J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
    Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
    Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
    Carvalho DP; Ferreira AC
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
    Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
    Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
    Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
    Singh TD; Song J; Kim J; Chin J; Ji HD; Lee JE; Lee SB; Yoon H; Yu JH; Kim SK; Yoon GS; Hwang H; Lee HW; Oh JM; Lee SW; Lee J; Choi HS; Na SY; Choi WI; Park YJ; Song YS; Kim YA; Lee IK; Cho SJ; Jeon YH
    Clin Cancer Res; 2019 Aug; 25(16):5069-5081. PubMed ID: 31010838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.